Dennis Slamon is a HER2/EGFR in Cancer Research physician affiliated with University of California, Los Angeles. OpenAlex indexes 990 publications with 101,582 citations (h-index 126); ClinicalTrials.gov lists 1 registered study with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 16 Oct 2026
Dennis Slamon, MD, is affiliated with University of California, Los Angeles. The public record shows 990 publications with 101,582 citations (h-index 126), centered on HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies, Monoclonal and Polyclonal Antibodies Research. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 8 companies, 10 NIH-funded awards (1985–2026).
- Most recent indexed publication: 2025 · Journal of the National Cancer Institute
- Top research focus: HER2/EGFR in Cancer Research
- 1 registered trials on ClinicalTrials.gov
- Open Payments reporting from 8 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 9 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 346.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:
- Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
Sponsor: Syndax Pharmaceuticals
Industry payments
Updated 16 Oct 2026
8 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20254 payments$17,699openpaymentsdata.cms.gov ↗
- Gilead Sciences, Inc.Program year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20251 payment
NIH funding
Updated 16 Oct 2026
10 NIH research awards on record, funded 1985–2026 per NIH RePORTER. The latest:
- Clinical Protocol and Data Management (CPDM)
University of California Los Angeles
FY2026$622,557P30CA016042 - Clinical Protocol and Data Management (CPDM)
University of California Los Angeles
FY2025$622,558P30CA016042
Congress activity
Updated 16 Oct 2026
164 congress contributions (2004–2026) across AACR, ASCO, ASH, ESMO, SABCS per OpenAlex. The most recent:
- Abstract 1323: Preclinical evaluation of target-mediated clearance and alternative payloads in CDH17-directed antibody drug conjugates.
AACR Annual Meeting
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients.
Journal of the National Cancer Institute
Clinical Trial2025 - Early Detection of Ovarian Cancer Using Cell-Free DNA Fragmentomes and Protein Biomarkers.
Cancer discovery
Article2025 - Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer.
Journal of clinical oncology
Clinical Trial2024
Most-cited works
by citation count (OpenAlex)- 01Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/<i>neu</i>OncogeneArticle11,770 citations1987
- 02
- 03Studies of the HER-2/ <i>neu</i> Proto-Oncogene in Human Breast and Ovarian CancerArticle6,860 citations1989
- 04Palbociclib and Letrozole in Advanced Breast CancerArticle2,982 citations2016
- 05
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/dennis-slamon-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/dennis-slamon-27516b103
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Dennis-J-Slamon-38237151
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
secondopinions.podbean.com/e/episode-1-dr-dennis-slamon
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →secondopinions.podbean.com ↗ - Other
nfcr.org/blog/episode-3-of-all-things-cancer-featuring-dr-dennis-slamon-now-available
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nfcr.org ↗ - X / Twitter
x.com/GOLDLab_UCD/status/1839618449544278478
- X / Twitter
x.com/ProfJohnCrown/status/1976622460754936282
- X / Twitter
x.com/TRIO_US_SMO/status/1092863414026653696
- YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Richard Casaburi, MD
University of California, Los Angeles
Robert Modlin, MD
University of California, Los Angeles
Zev Wainberg, MD
University of California, Los Angeles
John Belperio, MD
University of California, Los Angeles
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Eric Winer, MD
Yale School of Medicine
Hope Rugo, MD
City of Hope
Richard Finn, MD
David Geffen School of Medicine at UCLA